

Annual General Meeting

15 July 2009

This presentation and information communicated verbally to you may contain certain projections and other forward-looking statements with respect to the financial condition, results of operations and businesses of BTG plc (“BTG”). These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that will occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Although BTG currently believes that the assumptions underlying these forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and therefore there can be no assurance that any results contemplated in the forward-looking statements will actually be achieved. Nothing contained in this presentation or communicated verbally should be construed as a profit forecast or profit estimate. Investors or other recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. BTG undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances. Neither this presentation nor any verbal communication shall constitute an invitation or inducement to any person to subscribe for or otherwise acquire securities in BTG.

To build a self-sustaining international specialty pharmaceuticals business that brings to market products that deliver benefits to patients and give superior returns to shareholders

- Headquartered in London; listed on the LSE: BGC
- FTSE 250 member with a market cap of ~£400m
- Substantial revenues from licensed and marketed products; strong cash position of £78.2m*
- On track to achieve planned cost savings and synergies from integration of Protherics business
- Programmes partnered with AstraZeneca, Genzyme, Tolerx/GSK, Cougar Biotechnology/J&J and others providing potential additional milestones and royalties
- Broad pipeline of development programmes targeting cancer, neurological and other disorders
- Polyclonal manufacturing capability

BTG's global presence



~290 employees in Europe, North America, Australia and Japan

Three elements in our strategy:

1

Establish US commercial operation focussed on hospital specialist products in preparation for.....

2

Acquire further products targeting hospital specialists

3

Build value in and commercialise the development pipeline

- The return of marketing rights to the critical care products CroFab™ and DigiFab™
- The potential approval of Voraxaze™ for high dose methotrexate toxicity


...create a competitive commercial business selling our own products

1. Establishing US commercial operations

- CroFab™ (antivenom) and DigiFab™ (digoxin toxicity)
 - Intravenously administered polyclonal antibody fragments (Fab)
 - FDA approved, niche in-hospital products with limited competition
- Currently sold in the US by Nycomed
- US marketing rights return to BTG in October 2010
- Market opportunity:
 - CroFab™ ~ US\$80 million per annum
 - DigiFab™ ~ US\$30-35 million per annum, with the US market representing approximately US\$25 million per annum



1. Establishing US commercial operations



US specialist pharmaceutical sales force and back office support
~20 people (including 14 sales reps) anticipated

**Leverage the
sales and marketing infrastructure**

What?

- Niche products
- Lower development risk
- Competitive product profiles
- Long product lifecycles


Where?

- Hospitals
- Accessible through a small scale, targeted sales force

How?

- Acquisition
- Marketed products
- Late stage development

3. Build value in the development pipeline



*End of current development phase

**Decision on path of future development to be taken 2H 2009

Transition and Replace

- Voraxaze™ (treatment of delayed MTX elimination) – continue to progress through rolling BLA
- Varisolve® (varicose veins) – progress towards US Phase III pivotal trials and continue commercial discussions
 - Decision on future technical and commercial development in H2 09
- OncoGel™ (oesophageal cancer), Prolarix™ (primary liver cancer), Acadra™ (B-CLL), ATV (hypertension) – complete current clinical studies and seek partner
- BGC20-1531 (migraine) and BGC20-0134 (multiple sclerosis) – initiate and complete Phase II clinical studies and seek partner

MTX – methotrexate, an established cancer treatment

BLA – Biologics License Application

B-CLL – B-cell chronic lymphocytic leukaemia

- **Campath[®] – Genzyme Corporation**
 - Monoclonal antibody targeting the CD52 antigen
 - Approved as first-line treatment for B-cell chronic lymphocytic leukaemia (B-CLL) and in development for multiple sclerosis (MS)
 - Enrolment completed in one Phase III trial in multiple sclerosis and nearing completion in second Phase III trial
 - Data expected in 2011, potential approval in 2012
 - Genzyme has assumed sole responsibility for marketing Campath[®] in B-cell CLL and primary responsibility for development in MS



- **CB7630 (abiraterone acetate) – Cougar Biotechnology/J & J**
 - Orally active inhibitor of the steroidal enzyme complex 17 (hydroxylase/C17,20 lyase) involved in testosterone production
 - 2nd Phase III trial in CRPC patients initiated
 - Cougar plans to submit NDA/MAA based on progression-free survival data (co-primary endpoint with overall survival)
 - Johnson & Johnson recently announced a definitive agreement to acquire Cougar Biotechnology, Inc for approximately \$1.0 billion in a cash tender offer

■ TRX4 – Tolerx/GSK

- Humanised monoclonal antibody that binds to the CD3 receptors on T cells - designed to block the function of autoreactive T-effector cells that are implicated in autoimmune diseases
- Phase III trial in Type 1 diabetes initiated in August 08 progressing well; recruitment of EU patients started in March 09
- Recruitment under way in USA, Canada, Sweden, Finland, Italy, Germany, UK


■ CytoFab™ – AstraZeneca

- Ovine polyclonal antibody fragment (Fab) which neutralises TNF- α ; an inflammatory mediator strongly implicated in sepsis
- Manufactured in the same BTG facilities which successfully produce our other marketed Fab fragments: CroFab™ and DigiFab™
- Progressing well through Phase II study in Severe sepsis
- Study expected to finish around mid-2009 and decision on expanded Phase II study will follow




- Mission to build a self-sustaining international specialty pharmaceuticals business that brings to market products that deliver benefits to patients and give superior returns to shareholders
- Building blocks already in place:
 - US in-hospital sales force in 2010
 - Substantial financial resources
 - Multiple opportunities to create value from the development pipeline and partnered programmes

Clear pathway to becoming a sustainably profitable specialty pharmaceuticals company



Annual General Meeting – Q&A



Annual General Meeting – Close of Meeting